传染科指南

订阅

MedSci主页 / 所有栏目 / 传染科指南

2021 BHIVA指南：HIV-2的管理

2021-12-20 英国艾滋病协会 HIV Med

艾滋病HIV-2

2021年12月，英国艾滋病协会(BHIVA)发布了HIV-2的管理指南。人类免疫缺陷病毒（HIV）分为两个主要类型，即HIV-1和HIV-2。其中HIV-2有许多亚型且比HIV-1少见。

中文标题：

2021 BHIVA指南：HIV-2的管理

英文标题：

British HIV Association guidelines for the management of HIV-2 2021

发布机构：

英国艾滋病协会

发布日期：

2021-12-20

简要介绍：

2021年12月，英国艾滋病协会(BHIVA)发布了HIV-2的管理指南。人类免疫缺陷病毒（HIV）分为两个主要类型，即HIV-1和HIV-2。其中HIV-2有许多亚型且比HIV-1少见。据估计，全球约有100-200万HIV-2感染者，包括HIV-1和HIV-双重感染者。本文主要针对HIV-2的管理提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 BHIVA指南：HIV-2的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=901a71c00229863d, title=2021 BHIVA指南：HIV-2的管理, enTitle=British HIV Association guidelines for the management of HIV-2 2021, guiderFrom=HIV Med, authorId=0, author=, summary=2021年12月，英国艾滋病协会(BHIVA)发布了HIV-2的管理指南。人类免疫缺陷病毒（HIV）分为两个主要类型，即HIV-1和HIV-2。其中HIV-2有许多亚型且比HIV-1少见。, cover=https://img.medsci.cn/20211222/1640166234179_1608702.jpg, journalId=0, articlesId=null, associationId=81, associationName=英国艾滋病协会, associationIntro=英国艾滋病协会（BHIVA）已经成为英国领先的艾滋病专业协会。成立于1995年，它致力于为艾滋病感染者提供优质的服务。BHIVA还提供了一个艾滋病护理平台，有助于国际，国家和地方委员会处理艾滋病毒感染者的护理。, copyright=0, guiderPublishedTime=Mon Dec 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月，英国艾滋病协会(BHIVA)发布了HIV-2的管理指南。人类免疫缺陷病毒（HIV）分为两个主要类型，即HIV-1和HIV-2。其中HIV-2有许多亚型且比HIV-1少见。据估计，全球约有100-200万HIV-2感染者，包括HIV-1和HIV-双重感染者。本文主要针对HIV-2的管理提供指导建议。</span></p>, tagList=[TagDto(tagId=212, tagName=艾滋病), TagDto(tagId=120262, tagName=HIV-2)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=39, categoryName=皮肤性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=451, guiderKeyword=HIV, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7089, appHits=36, showAppHits=0, pcHits=401, showPcHits=7053, likes=0, shares=4, comments=4, approvalStatus=1, publishedTime=Wed Dec 22 17:39:54 CST 2021, publishedTimeString=2021-12-20, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Dec 22 17:51:29 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 22:19:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 BHIVA指南：HIV-2的管理.pdf)])
2021 BHIVA指南：HIV-2的管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179674, encodeId=383f11e967401, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:06 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179676, encodeId=228311e967623, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179675, encodeId=550b11e9675ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:10 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083758, encodeId=93291083e58b1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 24 06:58:52 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
    2022-01-02 一己怀

    谢谢，好东西

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179674, encodeId=383f11e967401, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:06 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179676, encodeId=228311e967623, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179675, encodeId=550b11e9675ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:10 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083758, encodeId=93291083e58b1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 24 06:58:52 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
    2022-01-02 一己怀

    谢谢，好东西

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179674, encodeId=383f11e967401, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:06 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179676, encodeId=228311e967623, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179675, encodeId=550b11e9675ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:10 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083758, encodeId=93291083e58b1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 24 06:58:52 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
    2022-01-02 一己怀

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1179674, encodeId=383f11e967401, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:06 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179676, encodeId=228311e967623, content=谢谢，好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179675, encodeId=550b11e9675ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 01:50:10 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083758, encodeId=93291083e58b1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 24 06:58:52 CST 2021, time=2021-12-24, status=1, ipAttribution=)]
    2021-12-24 微探

    学习学习

    0

相关指南

2021 WHO 关于 HIV 预防、检测、治疗、服务提供和监测的综合指南：对公共卫生方法的建议

世界卫生组织(WHO,The World Health Organization) · 2021-07-16

扩大艾滋病检测促进早检测专家共识

中国疾病预防控制中心性病艾滋病预防控制中心 · 2021-11-01

中国艾滋病诊疗指南（2021版）

中国疾病预防控制中心(CDC,Chinese Center For Disease Control And Prevention) · 2021-11-02

2020 BHIVA/BASHH/BIA指南：成人HIV检测

英国艾滋病协会(BHIVA,British HIV Association) · 2020-12-21

艾滋病相关焦虑中西医协同治疗专家共识

中华中医药学会(CACM,China Association of Chinese Medcine) · 2020-09-15

艾滋病合并高脂血症中西医协同治疗专家共识

中华中医药学会(CACM,China Association of Chinese Medcine) · 2020-08-10

拓展阅读

2010 OARAC 抗逆转录病毒药物使用指南：美国HIV感染孕妇（孕妇健康和减少围产期HIV传播）

艾滋病研究咨询理事会(OARAC,Office of AIDS Research Advisory Council) · 2010-01-01

2010 ACOG临床指南：感染HIV女性的妇科保健

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2010-12-20

WHO:资源匮乏地区HIV携带者的强化结核病例发现和异烟肼预防性治疗指南

世界卫生组织(WHO,The World Health Organization) · 2011-01-01

2011NIH 灾区感染HIV难民治疗指南-供非HIV专业医护人员使用

美国国家卫生研究院(NIH,The National Institutes of Health) · 2011-01-01

2011 OAR 对HIV - 1病毒感染的孕产妇建议使用抗逆转录病毒药物，以防止母婴传播

国家艾滋病研究所(OAR,HIN Office of ADIS Research) · 2011-01-01

2011 OAR 抗逆转录病毒药物的使用指南：感染HIV- 1的成年人和青少年

艾滋病研究咨询理事会(OARAC,Office of AIDS Research Advisory Council) · 2011-01-01